PTC Therapeutics
PTCT
183 hedge funds and large institutions have $2.48B invested in PTC Therapeutics in 2024 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 52 increasing their positions, 70 reducing their positions, and 22 closing their positions.
55% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 22
6% more funds holding
Funds holding: 172 → 183 (+11)
5% more capital invested
Capital invested by funds: $2.37B → $2.48B (+$114M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2.55% less ownership
Funds ownership: 113.8% → 111.25% (-2.6%)
26% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 70
72% less call options, than puts
Call options by funds: $5.09M | Put options by funds: $18.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$40.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$29.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.6M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$7.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$25.6M |
| 2 |
Jane Street
New York
|
-$20.3M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$15.1M |
| 4 |
State Street
Boston,
Massachusetts
|
-$14.7M |
| 5 |
Morgan Stanley
New York
|
-$12M |
PTCT Hedge Fund Activity: Q1 2024 in Review
183 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2024, worth a combined $2.48B — up 4.8% from $2.37B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PTCT positions and 22 closed out — a net gain of 12 holders — while 52 added to existing stakes and 70 trimmed.
The largest buyer was First Trust Advisors, opening a new position worth an estimated $40.2M. The largest seller was Wellington Management Group, cutting an estimated $25.6M.
- 183 institutional investors held PTC Therapeutics (PTCT) as of Q1 2024, up from 172 in Q4 2023.
- Funds reported $2.48B of PTC Therapeutics stock for Q1 2024, up 4.8% quarter-over-quarter.
- 34 funds opened new PTC Therapeutics positions in Q1 2024 and 22 closed out, a net change of +12 holders.
- The largest PTC Therapeutics buyer in Q1 2024 was First Trust Advisors, an estimated $40.2M added.
- The largest PTC Therapeutics seller in Q1 2024 was Wellington Management Group, an estimated $25.6M sold.
Based on aggregated 13F filings for Q1 2024.